Mercury Laboratories Limited , a pharmaceutical company, has announced a significant addition to its senior management team. Ms. Seema Salvi has been appointed as the Head of the Injectable Production Department, effective November 04, 2025. This appointment marks a strategic move in strengthening the company's production capabilities.

Key Appointment Details

Professional Background

Ms. Salvi brings a wealth of experience to her new role at Mercury Laboratories. With more than 26 years of expertise in injection production, she is well-positioned to lead the Injectable Production Department. Her extensive background in the pharmaceutical industry, particularly in injection manufacturing, aligns well with Mercury Laboratories' focus on quality healthcare products.

Regulatory Compliance

The appointment has been disclosed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory adherence underscores Mercury Laboratories' commitment to transparency in its corporate governance practices.

Implications for Mercury Laboratories

The addition of Ms. Salvi to the senior management team may potentially enhance Mercury Laboratories' capabilities in injectable drug production. Her extensive experience in the field could contribute to improving production processes, quality control, and overall efficiency in this critical department.

This strategic appointment reflects Mercury Laboratories' focus on strengthening its core operations and potentially expanding its injectable product portfolio. As the pharmaceutical industry continues to evolve, such experienced additions to the management team may help companies like Mercury Laboratories to adapt and grow in a competitive market.

Investors and industry observers may want to monitor how this appointment influences Mercury Laboratories' performance in the injectable drugs segment in the coming quarters.

Mercury Laboratories Limited, a pharmaceutical company, has reported robust financial results for the recent quarter, showcasing significant growth in both revenue and profitability.

Financial Highlights

• Total revenue increased by 8.9% year-over-year to ₹18.32 crore
• Net profit after tax surged by 183.3% to ₹96.76 lakh
• EBITDA margin expanded to 13.9% from 10.5% in the same quarter last year
• Revenue from operations grew by 8.7% to ₹18.14 crore
• Other income rose by 20.8% to ₹18.10 lakh

Operational Performance

The company's impressive financial performance can be attributed to several factors:

1. Higher Operating Leverage: Mercury Laboratories effectively utilized its existing resources to generate more revenue without a proportional increase in costs.

2. Improved Cost Management: The company implemented successful cost control measures, as evidenced by a 9.4% decrease in other expenses to ₹4.29 crore.

3. Favorable Product Mix: The shift towards higher-margin products contributed to the substantial improvement in profitability.

Cost Analysis

While Mercury Laboratories demonstrated strong overall performance, some cost components did see increases:

• Cost of materials consumed rose by 27.8% to ₹5.94 crore
• Employee expenses increased by 10.4% to ₹4.24 crore

Despite these increases, the company's effective cost management strategies and revenue growth led to a significant expansion in profitability.

Key Financial Metrics

The paid-up equity share capital of Mercury Laboratories remained unchanged at ₹1.20 crore.

This quarter's results demonstrate Mercury Laboratories' ability to drive revenue growth while significantly improving its bottom line through operational efficiencies and strategic product positioning.